Satoko Ito, MD, PhD
Postdoctoral FellowAbout
Research
Publications
2025
Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona R, Krumholz H, Croteau S, Cuker A, Goshua G. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Advances 2025 PMID: 40795232, DOI: 10.1182/bloodadvances.2025016822.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia AIntracranial hemorrhageEmicizumab prophylaxisHemophilia ASevere HAWTP thresholdStandard careProphylactic factor replacementUS societal perspectiveInfants Aged 0Markov cohort modelLifetime time horizonCost-effectiveness ratioProbabilistic sensitivity analysesFVIII inhibitorsBleeding riskFactor replacementSevere complicationsEmicizumabAccess placementCentral venous access placementPrimary outcomeProphylaxisNeurological disabilityCost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States.
Potnis K, Ito S, Kunst N, Richman I, Winer E, Goshua G. Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States. Journal Of Clinical Oncology 2025, 43: 11049-11049. DOI: 10.1200/jco.2025.43.16_suppl.11049.Peer-Reviewed Original ResearchHER2- early breast cancerEarly breast cancerIncremental cost-effectiveness ratioEndocrine therapyBreast cancerQuality-adjusted life yearsDeterministic sensitivity analysisHR-positiveHER2-negative early breast cancerWTP thresholdCost-effectiveness of ribociclibInvasive disease-free survivalDisease-free survival curvesAcceptable WTP thresholdDisease-free survivalBase-caseHigher WTP thresholdNonsteroidal aromatase inhibitorBase-case analysisCyclin-dependent kinase 4Cost-effectiveness ratioHER2-negativeCDK4/6 inhibitorsAromatase inhibitorsHealth system perspectiveAnchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A
Ito S, Sra M, Goshua G. Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A. PharmacoEconomics 2025, 43: 761-764. PMID: 40410545, PMCID: PMC12167127, DOI: 10.1007/s40273-025-01508-w.Peer-Reviewed Original ResearchCost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening
Ito S, Xicola R, Sra M, Potnis K, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz H, Llor X, Goshua G. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology And Hepatology 2025, 23: 2328-2338.e9. PMID: 40315972, PMCID: PMC12354148, DOI: 10.1016/j.cgh.2025.03.006.Peer-Reviewed Original ResearchLynch syndromeIncremental cost-effectiveness ratioGermline testingColorectal cancerProspective Lynch Syndrome DatabaseColorectal cancer probandsNational Cancer Institute's SurveillancePre-/post-interventionPreventing cancer incidenceLynch syndrome screeningEnd Results ProgramCost-effective interventionHealth system perspectiveCost-effectiveCancer incidenceQuality-adjusted life expectancyInstitute's SurveillanceResults ProgramProspective interventionStandard-of-careCost-effectiveness ratioLS testingCohort studyGenetic testingPrimary outcomeProphylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis.
Ito S, Potnis K, Harvey J, Sra M, Bewersdorf J, Bona R, Krumholz H, Cuker A, Pandya A, Goshua G. Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2025, 178: 819-828. PMID: 40258278, PMCID: PMC12170149, DOI: 10.7326/annals-24-02749.Peer-Reviewed Original ResearchConceptsEquity weightsSevere hemophilia AInequality aversion parameterFactor VIIIHemophilia AAversion parameterCost-effectiveness analysisEquity standardsCost-effectiveness of prophylaxisTime horizonOnce-weekly prophylaxisPriceAnnualized bleeding rateIncremental cost-effectiveness ratioFactor VIII prophylaxisScenario analysisCost-effectiveness ratioUnited StatesLifetime QALYsBleeding rateProphylaxisNational Institutes of HealthCost-effectiveInstitutes of HealthAlfaCost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women
Wang D, Sra M, Glaeser‐Khan S, Wang D, Moshashaian‐Asl R, Ito S, Cuker A, Goshua G. Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women. American Journal Of Hematology 2025, 100: 1132-1140. PMID: 40235279, PMCID: PMC12146817, DOI: 10.1002/ajh.27686.Peer-Reviewed Original ResearchConceptsWomen of reproductive ageFerritin thresholdIron deficiencyReproductive ageCost-effective interventionUS health system perspectiveNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyIncremental cost-effectiveness ratioCost-effectiveness of screeningTreatment of IDNutrition Examination SurveyMarkov cohort modelCost-effectiveness ratioProbabilistic sensitivity analysesHealth system perspectiveReproductive-agePrimary outcomeExamination SurveyLifetime QALYsDisability-adjusted life yearsIron repletionBase-caseFerritinID prevalenceUsing Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency
Goshua G, Varghese M, Ito S, Pandya A. Using Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency. Journal Of The American College Of Cardiology 2025, 85: 1376-1378. PMID: 40139895, PMCID: PMC12039621, DOI: 10.1016/j.jacc.2025.01.005.Peer-Reviewed Original Research
2024
Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.Peer-Reviewed Original ResearchSevere aplastic anemiaTreatment of severe aplastic anemiaQuality-adjusted life yearsAplastic anemiaIncremental net monetary benefitDeterministic sensitivity analysisProbabilistic sensitivity analysesImmunosuppressive therapyNewly diagnosed severe aplastic anemiaCost-effectiveness of eltrombopagOral thrombopoietin receptor agonistPatients treated with eltrombopagUntreated severe aplastic anemiaHematopoietic stem cell transplantationCost-effective therapeutic strategyDevelopment of adverse eventsLonger-term follow-up dataRACE trialsLater-line therapyThrombopoietin receptor agonistsPhase I/II trialSecond-line therapyStem cell transplantationU.S. payer perspectiveFirst-line treatmentIdentifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
Lam B, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Freed J, La J, Goshua G. Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule. Blood 2024, 144: 3669-3669. DOI: 10.1182/blood-2024-198033.Peer-Reviewed Original ResearchNegative predictive valueBeth Israel Deaconess Medical CenterClinical prediction rulePolycythemia veraIncremental net monetary benefitHealth resource utilizationPV patientsMyeloproliferative neoplasmsVA cohortTest characteristicsUS health system perspectivePrediction ruleAssociated with increased riskNon-fatal cardiovascular eventsExternal validation cohortAssociated with increased risk of strokeRandomized trial dataMarkov cohort modelLifetime time horizonProbabilistic sensitivity analysesRisk of strokePersistent erythrocytosisMedian ageHematologic malignanciesDiagnostic workupCost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
Wang D, Wang D, Glaeser-Khan S, Moshashaian Asl R, Chetlapalli K, Ito S, Cuker A, Goshua G. Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding. Blood 2024, 144: 281-281. DOI: 10.1182/blood-2024-198803.Peer-Reviewed Original ResearchSevere iron deficiency anemiaHeavy menstrual bleedingIron deficiency anemiaOral ferrous sulfateIncremental cost-effectiveness ratioIV iron sucroseIV iron dextranFirst-line treatmentFirst-lineIron sucroseQuality-adjusted life expectancyOral ironSecond-lineDeterministic sensitivity analysisProbabilistic sensitivity analysesIron dextranMenstrual bleedingDeficiency anemiaIron deficiencyUS health system perspectiveTreated with oral ironIV iron supplementationIV iron treatmentOral iron therapyDevelopment of iron deficiency
News
News
- December 05, 2024
Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder
- December 06, 2023
New Research Sheds Light on Equitable Treatment Options for Pediatric Patients With Sickle Cell Disease
- May 30, 2023
Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease
Get In Touch
Contacts
Email